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Rabies virus neutralizing antibody
a  b  s  t  r  a  c  t
Vampire  bat rabies  is  a  public  and  animal  health  concern  throughout  Latin  America.  As
part of an  ecological  study  of  vampire  bat depredation  on  cattle  in southern  Guatemala,
we conducted  a vaccine  seroconversion  study  among  three  dairy farms.  The  main  objec-
tives of  this  cross  sectional  and  cohort  study  were  to  understand  factors  associated  with
bat bites  among  cattle,  to  determine  whether  unvaccinated  cattle  had  evidence  of  rabies
virus exposure  and  evaluate  whether  exposure  was  related  to bat  bite prevalence,  and  to
assess whether  cattle  demonstrate  adequate  seroconversion  to two  commercial  vaccines
used  in Guatemala.  In  2012,  baseline  blood  samples  were  collected  immediately  prior  to
intramuscular  inoculation  of cattle  with  one  of  two modified  live  rabies  vaccines.  Post  vac-
cination  blood  samples  were  collected  13 and 393  days  later. Sera  were  tested  for rabies
virus neutralizing  antibodies  (rVNA)  by the  rapid  fluorescent  focus  inhibition  test  (RFFIT).
Across  two years  of  study,  36% (254/702)  of inspected  cattle  presented  gross  evidence  of
vampire  bat bites.  Individual  cattle  with  a  bat bite  in  2012  were  more  likely  have  a bat
bite  in 2013.  Prior  to vaccination,  12% (42/350)  of cattle  sera  demonstrated  rVNA,  but bite
status  in  2012  was  not  associated  with  presence  of rVNA.  Vaccine  brand  was  the  only  fac-
tor  associated  with  adequate  rVNA  response  of cattle  by day  13.  However,  vaccine  brand
and  rVNA  status  at day  13 were  associated  with  an  adequate  rVNA  titer on day  393,  with
animals  demonstrating  an  adequate  titer at day  13 more  likely  to  have  an  adequate  titer
at  day  393.  Our  findings  support  stable  levels  of vampire  bat depredation  and  evidence  of
rVNA in unvaccinated  cattle.  Brand  of  vaccine  may  be an  important  consideration  impacting
adequate  rVNA  response  and  long-term  maintenance  of  rVNA  in cattle.  Further,  the  results
demonstrate  that  initial  response  to vaccination  is  associated  with  rVNA  status  over  one
year following  vaccination.
Published  by  Elsevier  B.V.
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1. Introduction
Rabies is caused by infection with negative sense sin-
gle stranded RNA viruses in the genus Lyssavirus.  Rabies
virus is the most relevant member from an epidemiologi-
cal perspective, due to an estimated global human burden
in excess of 55,000 cases annually (Knobel et al., 2005).
While the global human burden is principally associated
with transmission cycles involving domestic dogs, bats are
an important reservoir and vector of rabies in the Ameri-
cas. Rabies outbreaks in cattle have been reported since the
early 20th century (Carini, 1911; Haupt and Rehaag, 1921).
Carini (1911) linked the outbreaks in cattle to wildlife, as
cases in dogs were rare at that time and canine popula-
tion reduction had no effect on the incidence of cases in
cattle. Haupt and Rehaag (1921) were able to isolate the
virus from a fruit bat (Artibeus lituratus), providing the
first evidence linking rabies in cattle with bats. However,
it was not until an outbreak in Trinidad that rabies virus
(RABV) was isolated from several naturally infected com-
mon vampire bats (Desmodus rotundus) and linked to the
disease in cattle and man  (Pawan, 1936). Thereafter, cattle
rabies was widely recognized in Latin America, with esti-
mated annual mortality of 0.5 million cattle and annual
economic losses of $47 million 1967 USD (∼$335 mil-
lion 2014 USD; www.bls.gov) despite estimated annual
vaccination of 2.7 million cattle (Acha, 1967). Cattle con-
tinue to be the primary sentinel animal associated with
RABV circulation in vampire bats and outbreaks through-
out Latin America. One study from Mexico demonstrated
a mean mortality rate of 10.3% among affected herds with
50 or more animals, with a range of 1.3% to 29% (Prieto
and Baer, 1972). As vaccination campaigns have reduced
the burden of canine rabies in Latin America, D. rotun-
dus has become the primary reservoir and vector of rabies
(Schneider et al., 2009). These obligate blood feeders pre-
fer cattle as a prey resource (Greenhall, 1988), though there
can be dietary flexibility where cattle are scarce (Delpietro
et al., 1992).
Experimental evidence supporting the utility of vac-
cination to protect cattle against bat rabies appear as
early as 1955 (Carneiro et al., 1955), and modified live or
nervous tissue vaccines were shown to reduce mortality
of cattle on affected farms during outbreaks (Prieto and
Baer, 1972). However, vaccination coverage among cattle,
as a preventative measure against rabies infection, tends
to be low (<5%) throughout most of Latin America (OIE,
2013), likely due to the relatively high cost of vaccinat-
ing large numbers of animals, turnover in herd animals
across years, and low perceived threat of rabies among
farmers. In Guatemala, the cattle population reported to
OIE from 2005 to 2012 fluctuated between 2.0 and 4.5 mil-
lion animals, with highest estimate in 2009 and lowest
in 2012 (OIE, 2013). During all years except 2009, vacci-
nation coverage was estimated to be between 0 and 2%
of the cattle population. In 2009, 0.5 million doses were
administered to cattle and coverage was estimated to be
11% of the cattle population. A recent study from Mexico
has demonstrated that pre-exposure vaccination of cattle
may  be more efficient and economically beneficial than
control efforts focused on depopulation of vampire bats
(Anderson et al., 2012). However, even if rabies risk was
removed from the equation, the secondary infections that
commonly result from vampire bat depredation still poses
a serious economic hardship for farmers in lost production
value of affected herds (Flores-Crespo and Arellano-Sota,
1991).
Historically in Guatemala, livestock farming was most
prolific in the southeastern region of the country. How-
ever, an increase in sugar cane and rubber production in
the southeastern region has spurred significant land use
conversion, and livestock farming and the associated bur-
den of rabies has primarily shifted to the northwestern
region of the country, though smaller dairy operations
remain active in the southeast. While the number of rabies
cases in dogs in Guatemala appears to be declining, the
number of cases in cattle has been rising steadily over
the past decade (OIE, 2013), though the impact of testing
effort is unclear due to the absence of reported denom-
inator data. As virus typing is not performed on positive
cases, it has not been possible to link the rise in cattle
cases with vampire bat rabies. However, this scenario is
most likely given the strong association of vampire bats
with cattle rabies outbreaks elsewhere throughout Latin
America and the high number of cattle cases and rare
occurrence of canine cases in some Departments (e.g.,
Petén, Alta Verapaz). Despite a lack of conclusive labo-
ratory evidence linking rabies in cattle to bats, vampire
bat control activities (i.e., poisoning or culling) are con-
ducted in Guatemala in response to suspected outbreaks
in cattle, although these are reactive strategies and spo-
radically applied. While they may  eliminate local colonies
of bats, and reduce bite incidence to cattle within a short
time frame, these strategies are ineffective at controlling
rabies virus circulation in vampire bats at a landscape scale.
Thus, vaccination is necessary to protect livestock against
rabies infection. During past suspected outbreaks, mass
vaccination of cattle was  initiated with assistance from
the Ministry of Agriculture (MAGA), but suspect clinical
cases of rabies in vaccinated cattle have raised concerns
about the efficacy of the vaccines used – as reported else-
where (Oliveira et al., 2000). There are several possibilities
regarding such cases, including scenarios that animals are
incubating the disease prior to vaccination, that the vaccine
was improperly stored or administered, that the animal
did not actually die of rabies (i.e., no lab confirmation of
case), or potential for reversion of virulence of the mod-
ified live vaccine (Whetstone et al., 1984). One recent
paper has highlighted the complexity of diagnosing rabies
based on clinical signs in areas where other neurologic
diseases of cattle can be present (Ramirez-Romero et al.,
2014).
The objectives of this study were to understand fac-
tors associated with bat bites among cattle, to determine
whether unvaccinated cattle had evidence of rabies virus
exposure and evaluate whether exposure was related to bat
bite prevalence, and to assess whether cattle demonstrate
adequate seroconversion to commercial modified live
rabies vaccines licensed in Mexico and used in Guatemala.
This study compares both the short-term response to two
different rabies vaccines and the maintenance of antibody
titers over one year post vaccination.
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2. Materials and methods
2.1. Animal sampling and treatments
The study design had elements of a cross sectional
and cohort nature. Bat bite prevalence among all animals
inspected at the farms, and seroprevalence of antibodies in
unvaccinated cattle, were investigated in a cross-sectional
design. Bat bite prevalence to individual animals across
years, and antibody response to vaccination, were inves-
tigated in a cohort design. Three dairy farms in the
municipality of Patulul, located in the Department of
Suchitepéquez, Guatemala, were enrolled in the vaccina-
tion study as a result of ongoing ecological studies of
vampire bats in the same area and capture of bats at or
near some of the farms. Farms were identified as A, B, and
C (Fig. 1). Each farm has a standing herd ranging from 100
to 200 cattle, and animals are bought, sold, and born in the
herds each year, though the rates of turnover vary across
the farms (e.g., C has the highest turnover rates and A the
lowest). All cattle over six months of age at each farm were
included in the study. Sex ratios in the herds tend to be
heavily skewed to females, with one or two breeding bulls
and a variable number of juvenile males. No animals in
the herds were reported as vaccinated against rabies by
the farm owners prior to the study. Protocols for animal
restraint and sampling were approved by the Centers for
Disease Control and Prevention (USA) and the Universi-
dad del Valle de Guatemala (Guatemala) Animal Care and
Use Committees. During February 7–9, 2012, cattle were
corralled and manually restrained to permit sampling and
vaccination. Cattle were visually inspected to determine
relative age, sex, and gross evidence of vampire bat bites
(e.g., open and/or bleeding lesions approximately 2–3 cm
in diameter). Approximate ages of cattle were available
at farm A, but in other cases relative ages were assigned
such that ‘juvenile’ refers to an animal less than 2 years
of age and ‘adult’ refers to an animal equal to or greater
than 2 years of age. A 3–5 ml  blood sample was collected by
venipuncture of the jugular or tail (coccygeal) vein immedi-
ately prior to intramuscular vaccination with 2 ml  of (one
of two) commercially available modified live rabies vac-
cines. Hereafter, these products are referred to as vaccine
‘A’ and vaccine ‘B’ to protect the identity of the manufactur-
ers. Vaccine A is made with the Evelyn Rokitnicki Abelseth
(ERA) strain of rabies virus, and vaccine B is made with the
Street Alabama Dufferin (SAD) strain. Vaccines were recon-
stituted on site using supplied sterile water according to
the manufacturer’s instructions, and were maintained on
ice packs in a styrofoam cooler until use (i.e., within 6 h
of reconstitution). Both products are licensed in Mexico
and labeled for use in large animals. Animals were arbi-
trarily assigned to one of the two vaccination treatment
groups during initial sampling, which resulted in greater
treatment applications of vaccine B (NA = 121, NB = 229). No
unvaccinated control animals were assigned or followed in
the study.
Cattle were corralled and manually restrained during
February 20–22, 2012 to collect a 13 day post vaccina-
tion blood sample. Farms were sampled in an identical
sequence. No visual inspection of bat bites was performed
during the day 13 follow up visit. During March 5–7, 2013,
393 days after vaccination, cattle were again corralled and
manually restrained for collection of a blood sample prior
to booster vaccination with 2 ml  of vaccine B. Selection of
vaccine B for booster vaccination was due to constraints
of product availability from the Guatemalan supplier of
vaccine A at the time of booster vaccination. During
2013 sampling, cattle were visually inspected to deter-
mine relative age, sex, and gross evidence of vampire bat
bites.
At farm A, cattle were identified by permanently
branded numbers, providing a unique and consistent form
of identification. At farm B, cattle were identifiable by
name, providing a unique and consistent form of identi-
fication. At farm C, 25 [milk] cattle were identifiable by
name, and temporary chemical brands of a two or three-
digit unique number were applied to all other farm C cattle
by MAGA personnel during the initial sampling in 2012.
Long-term re-sampling was not initially anticipated during
activities in 2012. While it was possible to read the chem-
ically branded numbers of farm C cattle at 13 days post
vaccination, it was no longer possible to read the num-
bers at 393 days post vaccination. Due to this factor, and
because it was not possible to re-sample the 25 cattle iden-
tified by name in 2013, farm C cattle were excluded from
day 393 analyses. Other animals lost during follow up were
necessarily excluded from day 13 or day 393 analyses.
Blood samples were kept out of direct sunlight during
sampling, and within 10 h of collection they were separated
by low-speed centrifugation for 10 min. Sera were trans-
ferred into 2 ml  cryovials using sterile pipettes, and stored
at −70 ◦C until shipment to the Rabies Laboratory at CDC in
Atlanta, GA, USA.
2.2. Detection of rabies virus neutralizing antibodies
Sera were assayed for rabies virus neutralizing antibod-
ies (rVNA) by rapid fluorescent focus inhibition test (RFFIT)
as described by Smith et al. (1996), and screened at 1:5 and
1:25 dilutions. Raw titers were converted to international
units (IU) by comparison to the positive control standard
rabies immune globulin (SRIG) containing 2 IU/ml, eval-
uated in each test in five-fold dilutions up to 1:625. The
cut-off threshold for seropositive rVNA status was  taken as
100% neutralization of virus at a 1:5 serum dilution, cor-
responding to titers equal to or greater than 0.10 IU/ml.
The threshold for adequate rVNA response was  taken as
50% or greater neutralization of virus at a 1:25 serum dilu-
tion, which corresponded to titers equal to or greater than
0.20 IU/ml. All positive sera (i.e., titer greater than or equal
to 0.10 IU/ml) were tested in duplicate or triplicate, and
geometric mean titers were used for the final evaluation in
relation to the cut-offs.
2.3. Statistical analyses
Contingency analyses were used to evaluate variation in
bite prevalence among all cattle at farms A, B and C during
2012 and 2013. Generalized linear mixed models (GLMs) of
a logistic nature were used to test for associations with five
binomial response variables. Farm was treated as a random
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Fig. 1. Map  of the study area and departments of Guatemala. The map  inset is the municipality of Patulul, located in the Department of Suchitepéquez.
Solid  circles show the locations of the three farms in the study.
effect in all GLMs to permit generalizing the results of this
study and to control for confounding effects of farm vari-
ation on certain fixed effect variables. Fixed effects in the
GLMs were binary, and included sex (male/female), relative
age (adult/juvenile), rVNA status (0/1), bite status (0/1), and
vaccine brand (A/B). Due to uneven sampling of relative age
and sex, an interaction term was included in GLMs where
applicable. For repeat observations of an individual animal,
a factor of the earlier status of the individual was included
as a fixed effect in the GLM to account for prior observa-
tions (e.g., bite or antibody status). Continuous age data
measured in years were available from cattle at farm A, and
logistic GLMs with age as the only fixed effect were tested
against response variables of interest when untreated or
log-transformed age data were normally distributed. When
untreated or log-transformed age data from farm A were
not normally distributed, a nonparametric ANOVA on the
ranks was used to test for an association of the response
variable with age. Pending the results of logistic GLMs using
a single fixed effect of age, multiple fixed effects were tested
with farm A data to evaluate the effect of age while con-
trolling for other binary variables described above. Logistic
GLMs (PROC GLIMMIX) and other analyses were run using
SAS v9.2 (SAS Institute, Cary, NC). Estimates and standard
error for farm, the random effect covariance parameter, are
shown for each mixed GLM evaluated. Odds ratios (OR)
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Table  1
Demographic data for the cohort of cattle sampled at three farms in 2012 and re-sampled in 2013.
Farm 2012 2013
Adults Juveniles Total Adults Juveniles Total
Male Female Male Female Male Female Male Female
A 1 154 0 0 155 1 81 0 0 82
B  3 94 0 25 122 2 73 0 5 80
C  4 52 26 34 116 0 0 0 0 0
Total  8 300 26 59 393 3 154 0 5 162
Table 2
The number of cattle inspected and proportion demonstrating evidence of bat bites during cross sectional surveys in 2012, 2013, and cumulatively at three
farms  in Patulul, Guatemala.
Farm 2012 2013 Cumulative
N Proportion with bites N Proportion with bites N Proportion with bites
A 155 0.43 115 0.71 270 0.55
B  122 0.09 127 0.31 249 0.20
C  116 0.20 67 0.49 183 0.31
Total  393 0.25 309 0.50 702 0.36
were calculated for significant fixed effects (  ˛ = 0.05), with
95% confidence limits.
3. Results
A total of 393 cattle were sampled and vaccinated during
the initial visit in 2012 (Table 1). Based on unique per-
manent identification present at farms A and B in 2012,
it could be determined that 58% of 277 cattle sampled from
those two farms were resampled in 2013. Due to temporary
chemical brand identification applied to cattle at farm C in
2012, and inaccessibility of the uniquely named farm C cat-
tle in 2013, it was not possible to determine whether any of
the 116 cattle sampled at farm C in 2012 were resampled
in 2013.
3.1. Bat bite prevalence among cattle
Prevalence of bat bites among cattle at the farms var-
ied between years (Table 2). Bite prevalence across farms
varied in 2012 (2 = 43.3, P < 0.0001) and in 2013 (2 = 39.8,
P < 0.0001) (Table 2). In comparisons of cross-sectional bite
data from 2012 to 2013 (Table 2), year was associated
with bite prevalence (year F1,698 = 53.4, P < 0.0001, OR 3.7
[95% CL 2.6–5.3], farm 0.83 ± 0.86) and cattle in 2013 were
more likely to be bitten. In the 2012 cohort, sex was the
only factor associated with bite status and males were
more likely to be bitten compared to females (Table 3,
Model 1; sex F1,387 = 4.3, P = 0.04, OR 3.0 [95% CL 1.1–8.7],
farm = 1.13 ± 1.20). From the 2012 cohort, 162 cattle were
re-inspected in 2013 (Table 3, Model 2). Animals bitten in
2012 were more likely to have evidence of bites in 2013
(2012 bite status F1,159 = 9.5, P = 0.002; OR = 4.0 [95% CL
1.6–9.5], farm = 0.88 ± 1.34).
In the farm A cross sectional data from 2012 to
2013 (Table 2), neither age nor log-transformed age
data were normally distributed. Although none of the
farm A cattle sampled were juveniles (range2012: 2–16
years, median2012 = 7.5 years; range2013: 2.5–17 years,
Table 3
A description of generalized linear mixed models evaluated in the cohort
study. Farm was treated as a random effect in each model. Fixed effects in
bold text were significant for a given model.
Model N Response variable Fixed effects
Predictors of bite status
(1) 393 2012 bite status Relative age, sex,
relative age × sex
(2)  162a,b 2013 bite status 2012 bite status
Predictors of rVNA in unvaccinated animals
(3) 350 Day 0 rVNAc Relative age, sex, 2012
bite status
Predictors of response to rabies vaccination
(4) 318 Day 13 rVNAd Relative age, sex, 2012
bite status, vaccine
brand, day 0 rVNA
status, relative
age × sex
(5)  133a,b Day 393 rVNAd 2013 bite status,
vaccine brand, day 0
rVNA status, day 13
rVNA status
a Less than five males sampled; sex not included.
b Five juveniles sampled total; relative age not included.
c Evaluated at rVNA greater than or equal to 0.10 IU/ml.
d Evaluated at rVNA greater than or equal to 0.20 IU/ml.
median2013: 7 years), age was  associated with bite status
in the cross sectional 2012 data and younger animals were
more likely to be bitten in a nonparametric ANOVA on the
ranks (F1,142 = 12.4, P = 0.0006). In the cross sectional data
from farm A in 2013 (n = 115), a similar trend was observed
with younger animals more likely to be bitten in a nonpara-
metric ANOVA on the ranks (P = 0.09).
3.2. Rabies antibodies in unvaccinated cattle
Among 393 cattle sampled prior to vaccination in 2012,
rVNA titers were determined from 89% of 393 animals.
Of 350 cattle sera tested, 12% of sera presented evi-
dence of rVNA prior to vaccination (Table 4). The rVNA
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Table  4
The proportion of cattle in the cohort study with pre and post vaccination rabies virus neutralizing antibody titers of cattle at three farms in Patulul,
Guatemala.
Farm Day 0 Day 13 Day 393
N ≥0.10a Nb ≥0.10 ≥0.20a Nb ≥0.10 ≥0.20
A 114 0.06 102 0.57 0.40 54 0.24 0.13
B  120 0.04 111 0.61 0.47 71 0.31 0.20
C  116 0.26 73 0.67 0.49 0 – –
Total  350 0.12 286 0.61 0.45 125 0.28 0.17
a Rabies virus neutralizing antibody titer cut-off (IU/ml).
b Includes only animals seronegative at baseline (day 0).
seroprevalence in unvaccinated cattle varied across farms
(2 = 31.8, P < 0.0001), with farm C (26%) having higher anti-
body prevalence compared to farm A (6%) and farm B (4%).
However, the presence of rVNA in unvaccinated cattle was
not associated with the animal’s bite status in 2012, sex nor
relative age (Table 3, Model 3; farm = 1.01 ± 1.13). Among
cattle sera tested at the farm A, log age data were normally
distributed, but the presence of rVNA in unvaccinated cattle
was not associated with log age.
3.3. Antibody response of cattle to vaccination
Day 13 post vaccination rVNA titers were determined
from 318 cattle with a known baseline titer (Table 4).
Among cattle that were rVNA negative prior to vaccina-
tion and sampled at day 13 (n = 286), 45% demonstrated
an adequate rVNA response 13 days post vaccination
(i.e., titer ≥ 0.20 IU/ml), whereas 61% were rVNA seropos-
itive (i.e., titer ≥ 0.10 IU/ml). Among cattle that were rVNA
seropositive prior to vaccination and sampled at day 13
(n = 32), 59% demonstrated an adequate rVNA response 13
days post vaccination, whereas 78% were rVNA seroposi-
tive. Among all 318 cattle with sera evaluated at day 0 and
day 13 post vaccination (Table 3, Model 4), vaccine brand
was the only factor associated with an adequate rVNA
response at day 13 (vaccine brand F1,309 = 24.0, P < 0.0001,
OR 3.6 [95% CL 2.2–6.0], farm = 0.06 ± 0.12), and cattle
treated with vaccine A were more likely to demonstrate an
adequate titer by day 13 compared to cattle treated with
vaccine B. An adequate response by day 13 was marginally
associated with baseline rVNA status (P = 0.08), and cattle
seropositive at baseline were more likely to demonstrate
an adequate rVNA response by day 13. An adequate rVNA
response at day 13 was not associated with relative age,
sex, a relative age by sex interaction term, nor 2012 bite
status. Among cattle at farm A with titers evaluated at day
0 and day 13 post vaccination, log age data were normally
distributed, but an adequate rVNA response was  not asso-
ciated with log age.
Among cattle that were seronegative prior to vaccina-
tion in 2012 and sampled at days 13 and 393 (n = 125), 17%
demonstrated an adequate rVNA titer at day 393, whereas
28% were seropositive (Table 4). Among cattle that were
seropositive prior to vaccination in 2012 and sampled at
days 13 and 393 (n = 8), 13% demonstrated an adequate
rVNA titer at day 393, whereas 63% were seropositive.
Among cattle sampled longitudinally across all time points
(Table 3, Model 5), vaccine brand (vaccine brand F1,127 = 6.0,
P = 0.02, OR 3.6 [95% CL 1.3–10.4]) and rVNA status at day
13 post vaccination (day 13 status F1,127 = 7.6, P = 0.007, OR
4.4[95% CL 1.5–12.8]) were associated with an adequate
rVNA titer at day 393 post vaccination (farm = 0.40 ± 0.81).
Similar to the day 13 results, cattle that received vaccine A
were more likely to have an adequate rVNA titer at day 393.
Cattle which demonstrated an adequate rVNA titer at day
13 post vaccination were more likely to have an adequate
titer at day 393. Cattle with evidence of a bat bite in 2013
were marginally more likely to have an adequate rVNA titer
at day 393 (P = 0.10). Baseline rVNA status was not associ-
ated with an adequate rVNA response at day 393. At farm
A, log age data were normally distributed, but an adequate
rVNA response at day 393 was  not associated with log age.
4. Discussion
Vampire bat depredation is a well-recognized public
and veterinary health concern throughout Latin America,
and the risk of rabies, a highly fatal zoonosis, is clearly
the most high profile infection risk posed by vampire bat
bites. Other relevant health risks associated with vampire
bat depredation of cattle include secondary infections that
result from the open wounds left by bats after feeding,
although data on lost production value due to blood loss
alone have been equivocal (Flores-Crespo and Arellano-
Sota, 1991). Despite this, relatively low proportions of
farmers in Latin America vaccinate their cattle against
rabies. Literature has suggested that vampire bats may be
loyal to stable and reliable food sources (de Verteuil and
Urich, 1936). While the feeding behaviors of individual
vampire bats were not monitored during the study period,
individual bat fidelity to foraging grounds (i.e., cattle pas-
tures) was  observed during a three week radiotracking
study in 2011 at the farm A involving 16 D. rotundus (AG,
unpublished data). Vampire bat roosts (est. 20–50 bats)
were visually located within 2 km proximity to farms A and
C during 2012, but no bat roost was  visually located in prox-
imity to B. The results of the current study demonstrate
nonrandom attacks on cattle across years, where certain
cattle suffer repeated depredation by vampire bats over
time. Where approximate cattle ages were known at farm
A, younger cattle were more likely to be bitten compared
to older cattle, although all farm A cattle sampled were
considered adults.
Despite the relatively high prevalence of vampire bat
bites on cattle during the two-year study period, it is
equally noteworthy that only two  cases of cattle rabies
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were reported to OIE during 2005–2012 from the Depart-
ment of Suchitepéquez (one in 2010, one in 2011), whereas
102 cases of cattle rabies were reported from the north-
ern Department of Petén and 50 cattle cases reported
from the northern Department of Alta Verapaz during
the same time period (OIE, 2013). While geographic
area or population size of the Departments may  be a
factor (Fig. 1), area-corrected cattle rabies incidence is
still three to six times as high in the northern Depart-
ments of Petén (2.8 × 10−3 cases/km2) and Alta Verapaz
(5.1 × 10−3 cases/km2) in comparison to Suchitepéquez
(8.3 × 10−4 cases/km2). The population corrected inci-
dence, using the average projected population from 2005
to 2010 of the three Departments (I.N.E., 2008), shows sim-
ilar trends (Petén – 10 cases per 100,000 pop, Alta Verapaz
– 9 cases per 100,000 pop, Suchitepéquez – 0.42 cases
per 100,000 pop). However, during the same time period,
45 cases of dog rabies were reported from Suchitepéquez,
in contrast to two dog cases from Alta Verapaz and five
dog cases from Petén, suggesting that canine rabies is of
greater concern in the southwestern Departments. As a
result, we cannot rule out that some rabies virus exposures
in unvaccinated cattle that were detected in this study
might also be due to contact with dogs, although the eco-
logical link with vampire bats is clearly stronger. Despite
this, reports of cattle rabies in Guatemala appear to be on
the rise in recent years, though a lack of variant typing has
precluded direct association with vampire bat RABV, and
the absence of reported rabies cases in bats leaves many
questions. A low proportion of clinically suspect cattle are
subject to diagnostic testing by the national laboratories
in Guatemala, primarily due to difficulties with sample
transport and cold chain maintenance, as likely occurs else-
where in Latin America (Baer, 1991). Thus, the current
passive surveillance system underestimates the true bur-
den of cattle rabies in the country. Although independent
surveillance of bats in this study area (i.e., at farm A) did
not provide serologic evidence of rabies virus circulation
in 2011, there is strong evidence of rabies virus circulation
among bats in nearby localities based on rVNA seropreva-
lence and virus isolation (Ellison et al., 2014). The detection
of rVNA in unvaccinated cattle suggests prior exposure of
cattle to RABV in the study area, and may  be associated with
the repeated vampire bat depredation as observed during
the study. None of the cattle were reported by farm owners
to have been vaccinated prior to the study and, with a sin-
gle exception (i.e., the bull), all animals sampled at farm A
were born and raised on that farm. It is unclear why there
were lower proportions of unvaccinated cattle with rVNA
detected in 2012 at farms A (6%) and B (4%) compared to
farm C (26%), but an unrecognized history of vaccination
may  have been possible at farms B and C. However, at farm
A, where animal records, identification and animal reten-
tion were highly reliable, we can confirm that all seven
unvaccinated animals with rVNA at day 0 had been on that
farm for the past 5–11 years (i.e., since birth).
The rVNA response to vaccination with rabies vaccines is
well studied in livestock (Prosperi et al., 1984; Cortes et al.,
1993; da Silva et al., 2000; Oliveira et al., 2000), and most
prior work has compared responses to live versus inactiv-
ated rabies vaccines. An [adjuvanted] inactivated vaccine
produced more robust rVNA responses than a modified live
vaccine following a single dose regimen in cattle in one
study (Prosperi et al., 1984), but a subsequent study found
weak stimulation of antibodies from a single dose admin-
istration of inactivated or modified live vaccines (Oliveira
et al., 2000). However, stimulation of cell-mediated immu-
nity by [replication of] modified live vaccines may confer
additional resistance to rabies challenge even where rVNA
induction appears suboptimal. The RABV glycoprotein (G)
is the primary antigen responsible for induction of rVNA
(Wiktor et al., 1973). The peak rVNA response to vacci-
nation with rabies vaccines typically is observed 14–28
days following vaccination, and thus the timing of samp-
ling periods in this study may  have precluded detection of
maximal proportions of animals with adequate rVNA, and
potential underestimation of rVNA response to vaccination.
Despite this, an adequate rVNA response was detected on
day 13 in nearly half of the animals, and closer to two-thirds
showed at least some evidence of rVNA seroconversion
on day 13. Although this study did not quantify endpoint
titers to facilitate analysis of an anamnestic response, cattle
that were seropositive prior to vaccination seroconverted
in greater proportions than seronegative cattle.
There was no association of relative age or sex on
the development of an adequate rVNA response by cat-
tle at day 13. Although outside the scope of the current
study, additional investigation is warranted to determine
whether physiological parameters of an animal’s health
could explain the individual variation in serologic response
observed in this study. One potential confounding factor
for the low proportion of study animals with adequate
responses at day 13 may  relate to the lack of random-
ization in the treatment schema, as two-thirds of 393
cattle received vaccine B on day 0. Results unequivocally
indicated an effect of vaccine brand on development of
adequate rVNA among cattle on days 13 and 393 post vac-
cination. Among 286 cattle seronegative on day 0, 63% of 99
cattle treated with vaccine A had an adequate titer, whereas
36% of 187 cattle treated with vaccine B had an adequate
titer on day 13. Although vaccine B appears to be less
immunogenic to cattle in this study, warranting follow-up
comparative investigations of potency, we  cannot conclude
from these data that vaccine B is less efficacious in con-
ferring resistance to RABV infection in vaccinated cattle.
The form of G presentation was found to be an impor-
tant factor affecting immunogenicity in mice (Dietzschold
et al., 1983). A study in Brazil also demonstrated the impor-
tance of the form of G presentation for rVNA response in
cattle, where virion-attached G was the only significant
predictor of rVNA response, when compared with total G
or free-soluble G (Piza et al., 2002). The same study also did
not find a correlation between vaccine potency, measured
in vivo by the standard NIH (i.e., mouse inoculation) test,
and rVNA induction in cattle (Piza et al., 2002). More lab-
oratory studies of the composition of the vaccines utilized
in this study are needed to understand the variation due to
vaccine brand observed in this study.
Among 133 animals in the study cohort through 2013,
40% of 57 animals with an adequate titer on day 13
were rVNA seropositive over one year later. However, one
confounding factor for the long-term follow up was  the
A. Gilbert et al. / Preventive Veterinary Medicine 118 (2015) 36–44 43
absence of an unvaccinated seronegative control group to
evaluate the impact of potential natural RABV exposures
from vampire bats or other animals in the study area.
Given the detection of rVNA in unvaccinated cattle and the
marginal association of 2013 bite status with presence of
adequate titers on day 393, natural exposures to RABV from
bat (or dog) bites to cattle may  have influenced rVNA titers
on day 393. The low proportions of animals with adequate
titers at day 13 and over one year later are not surprising
given other studies which have shown weak rVNA response
and maintenance to single doses of modified live vaccines
(da Silva et al., 2000; Oliveira et al., 2000), and collectively
these studies underscore the importance of annual booster
vaccination. Moreover, rVNA titers may  not correlate with
protection against rabies and there is no agreed upon level
deemed protective, as there may  be other immunologi-
cal factors impacting resistance or susceptibility to rabies
(Moore and Hanlon, 2010).
5. Conclusions
Vaccination of incidental hosts such as livestock and
companion animals is a key tool to protect against RABV
infection, especially in areas where there is evidence of
repeated depredation by vampire bats. Given the apparent
rise in significance of vampire bat rabies for Latin Amer-
ica as a whole, and as observed from increasing numbers
of laboratory confirmed cases in Guatemala in particular,
the importance of vaccinating valuable production animals
should not be overlooked. Enhanced [active] rabies virus
surveillance among bats in Guatemala also demonstrated
that the risk of RABV infection associated with bats is geo-
graphically widespread. The risk of RABV infection is clearly
highest among cattle that are repeatedly bitten by bats,
and in this study bite status in one year was associated
with bite status the following year, although bite status was
not associated with the presence of rVNA in unvaccinated
animals. Vaccine brand was an important factor both in
the initial response and long-term maintenance of an ade-
quate rVNA response, though additional laboratory studies
are needed to understand the basis for these differences.
The initial rVNA response to vaccination was associated
with the long-term maintenance of adequate rVNA titers
in cattle sampled longitudinally. The results of this study
demonstrate that cattle respond to intramuscular vaccina-
tion with commercial modified live vaccines in Guatemala,
and that relative age and sex of the animals are not associ-
ated with the initial rVNA response to vaccination.
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